Mode
Text Size
Log in / Sign up
N/A N=31 Randomized Treatment

Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome

Sleep-disordered Breathing · Snoring

Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Pleural Pressure (Pes) — 9.3; 4.4 mmHg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CPAP (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Dec 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Pleural Pressure (Pes)
9.3; 4.4
PRIMARY
Mean Arterial Blood Pressure (MAP)
93.8; 88.3
SECONDARY
Augmentation Index (AI)
11.0; 2.4
SECONDARY
Reactive Hyperemia Index (RHI)
2.2; 2.2

Summary

Upper airway obstruction (UAO) is an unrecognized source of hemodynamic stress that may contribute to aortic adverse events in persons with Marfan Syndrome (MFS). UAO occurs during snoring and sleep apnea and is characterized by repetitive partial or complete obstruction of the upper airway during sleep. These obstructive breathing events lead to intermittent surges in blood pressure (BP) REF and large decreases in pleural pressure (Pes), thereby increasing the trans-mural aortic pressure (TMP) and imposing mechanical stress on the aorta during sleep. Although UAO is known to increase mechanical stress on the aorta, the magnitude of the increase is not known for persons with MFS. In this project, therefore, the investigators will also examine the changes in Pes and BP responses in periods of obstructed breathing and compare the diurnal markers or vascular stress between Baseline and CPAP studies in MFS persons.

Eligibility Criteria

Inclusion Criteria

People with Marfan syndrome.

  • Age ≥ 18yrs
  • Able and willing to provide informed consent
  • Willing to sleep connected to research apparatus

Exclusion Criteria

  • Unstable cardiovascular disease (CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
  • Uncontrolled hypertension (BP > 190/110)
  • Underlying obstructive or other intrinsic lung disease
  • Renal failure on dialysis
  • Cirrhosis
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03985657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search